TECENTRIQ or IMFINZI, a human PD-L1 blocking antibody, is used for stage II to IIIA NSCLC (PD-L1 expression ≥1%) as adjuvant treatment following platinum-based chemotherapy, meanwhile, in combination with carboplatin and etoposide for extensive-stage small cell lung cancer (ES-SCLC). Here, CD274 is linked to non-small cell lung carcinoma.